

Supplemental Digital Content 3. Snapshot Outcomes at Week 144 in the ITT-E Population From GEMINI-1, GEMINI-2, and Pooled

Snapshot outcome, n (%)	GEMINI-1		GEMINI-2		Pooled	
	DTG + 3TC (N=356)	DTG + TDF/FTC (N=358)	DTG + 3TC (N=360)	DTG + TDF/FTC (N=359)	DTG + 3TC (N=716)	DTG + TDF/FTC (N=717)
HIV-1 RNA <50 copies/mL	281 (79)	296 (83)	303 (84)	303 (84)	584 (82)	599 (84)
HIV-1 RNA ≥50 copies/mL	14 (4)	11 (3)	9 (3)	10 (3)	23 (3)	21 (3)
Data in window and HIV-1 RNA ≥50 copies/mL	4 (1)	3 (1)	0	2 (<1)	4 (<1)	5 (<1)
Discontinued for lack of efficacy	4 (1)	3 (1)	6 (2)	1 (<1)	10 (1)	4 (<1)
Discontinued for other reason and HIV-1 RNA ≥50 copies/mL	5 (1)	5 (1)	2 (<1)	6 (2)	7 (1)	11 (2)
Change in ART	1 (<1)	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
No virologic data at Week 144	61 (17)	51 (14)	48 (13)	46 (13)	109 (15)	97 (14)
Discontinued study because of AE or death	17 (5)	20 (6)	12 (3)	12 (3)	29 (4)	32 (4)
Discontinued study for other reasons	42 (12)	30 (8)	36 (10)	34 (9)	78 (11)	64 (9)
Withdrew consent	14 (4)	11 (3)	16 (4)	14 (4)	30 (4)	25 (3)
Lost to follow-up	14 (4)	8 (2)	11 (3)	11 (3)	25 (3)	19 (3)
Protocol deviation	6 (2)	6 (2)	5 (1)	3 (1)	11 (2)	9 (1)
Physician decision	8 (2)	5 (1)	3 (1)	5 (1)	11 (2)	10 (1)
Lack of efficacy	0	0	1 (<1) ^a	1 (<1) ^a	1 (<1) ^a	1 (<1) ^a
On study but missing data in window	2 (<1)	1 (<1)	0	0	2 (<1)	1 (<1)

AE, adverse event; ART, antiretroviral therapy; CVW, confirmed virologic withdrawal; DTG, dolutegravir; FTC, emtricitabine; ITT-E, intention-to-treat–exposed; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.

^aParticipant had HIV-1 RNA <50 copies/mL after meeting CVW criteria.